Cited by 317Genetic Associations and EpidemiologyLipoproteins and Cardiovascular HealthAlzheimer's disease research and treatments

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank

Open access

Abstract

Background The three main alleles of the APOE gene (ε4, ε3 and ε2) carry differential risks for conditions including Alzheimer's disease (AD) and cardiovascular disease. Due to their clinical significance, we explored disease associations of the APOE genotypes using a hypothesis-free, data-driven, phenome-wide association study (PheWAS) approach. Methods We used data from the UK Biobank to screen for associations between APOE genotypes and over 950 disease outcomes using genotype ε3ε3 as a reference. Data was restricted to 337,484 white British participants (aged 37–73 years). Findings After correction for multiple testing, PheWAS analyses identified associations with 37 outcomes, representing 18 distinct diseases. As expected, ε3ε4 and ε4ε4 genotypes associated with increased odds of AD (p ≤ 7.6 × 10 −46 ), hypercholesterolaemia (p ≤ 7.1 × 10 −17 ) and ischaemic heart disease (p ≤ 2.3 × 10 −4 ), while ε2ε3 provided protection for the latter two conditions (p ≤ 3.7 × 10 −10 ) compared to ε3ε3. In contrast, ε4-associated disease protection was seen against obesity, chronic airway obstruction, type 2 diabetes, gallbladder disease, and liver disease (all p ≤ 5.2 × 10 −4 ) while ε2ε2 homozygosity increased risks of peripheral vascular disease, thromboembolism, arterial aneurysm, peptic ulcer, cervical disorders, and hallux valgus (all p ≤ 6.1 × 10 −4 ). Sensitivity analyses using brain neuroimaging, blood biochemistry, anthropometric, and spirometric biomarkers supported the PheWAS findings on APOE associations with respective disease outcomes. Interpretation PheWAS confirms strong associations between APOE and AD, hypercholesterolaemia, and ischaemic heart disease, and suggests potential ε4-associated disease protection and harmful effects of the ε2ε2 genotype, for several conditions. Funding National Health and Medical Research Council of Australia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2020.102954

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 APOE genotypes and risk of disease. Forest plots depicting the OR (black box symbols) and 95% CI (horizontal lines) for each genotype compared to reference genotype, ε3ε3. Data is presented for representative disease outcomes where at least one genotype showed a signal in the PheWAS. Actual values are shown to the right of each graph. Case and control numbers and p-values (logistic regression) for each comparison group can be found in table S4 (appendix pp 8–32), with further breakdown by genotype shown within figures S3–S7 (appendix pp 36–40). “Other aneurysm” encompasses aortic, and other arterial aneurysms, but not cerebral, or heart aneurysms. “Other cerebral degenerations” includes gangliosidosis, sphingolipidosis, neuronal ceroid lipofuscinosis, Rett syndrome, Reye syndrome, systemic atrophy primarily affecting the central nervous system, and degeneration of the nervous system due to alcohol. “Nutrition, metabolism and development symptoms” pertains to symptoms including severe protein-energy malnutrition, feeding difficulties and mismanagement, and abnormal weight loss.
Fig. 1 APOE genotypes and risk of disease. Forest plots depicting the OR (black box symbols) and 95% CI (horizontal lines) for each genotype compared to reference genotype, ε3ε3. Data is presented for representative disease outcomes where at least one genotype showed a signal in the PheWAS. Actual values are shown to the right of each graph. Case and control numbers and p-values (logistic regression) for each comparison group can be found in table S4 (appendix pp 8–32), with further breakdown by genotype shown within figures S3–S7 (appendix pp 36–40). “Other aneurysm” encompasses aortic, and other arterial aneurysms, but not cerebral, or heart aneurysms. “Other cerebral degenerations” includes gangliosidosis, sphingolipidosis, neuronal ceroid lipofuscinosis, Rett syndrome, Reye syndrome, systemic atrophy primarily affecting the central nervous system, and degeneration of the nervous system due to alcohol. “Nutrition, metabolism and development symptoms” pertains to symptoms including severe protein-energy malnutrition, feeding difficulties and mismanagement, and abnormal weight loss.CC BY-NC-ND · PubMed Central
Fig. 2 APOE genotypes and differences in biomarkers Graphs are displayed as standardised mean differences in biomarker levels for each APOE genotype with reference to ε3ε3. The values on the right correspond to absolute mean difference values (β) and 95% CI. *Note that for white matter hyperintensity (WMH) volume (E), the plotted data were inverse normal transformed to approximate normal distribution, while the volume values presented to the right are natural values. The panel includes markers related to brain health (A–E), cardiovascular risk (F–M), diabetes (N–O), obesity (P–R), and lung health (S–U). Population numbers and p-value (linear regression) for each biomarker can be found in table S5 (appendix p 33). APOA: apolipoprotein A. APOB: apolipoprotein B. BMI: Body mass index. CRP: C-reactive protein. FEV1: Forced expiratory volume during one second. FVC: Forced vital capacity. HbA1c: Haemoglobin A1c (glycated haemoglobin). HDL: high density lipoprotein. LDL: low density lipoprotein. Lp(A): lipoprotein A. WC: waist circumference. WHR: waist-hip ratio. WMH: white matter hyperintensity.
Fig. 2 APOE genotypes and differences in biomarkers Graphs are displayed as standardised mean differences in biomarker levels for each APOE genotype with reference to ε3ε3. The values on the right correspond to absolute mean difference values (β) and 95% CI. *Note that for white matter hyperintensity (WMH) volume (E), the plotted data were inverse normal transformed to approximate normal distribution, while the volume values presented to the right are natural values. The panel includes markers related to brain health (A–E), cardiovascular risk (F–M), diabetes (N–O), obesity (P–R), and lung health (S–U). Population numbers and p-value (linear regression) for each biomarker can be found in table S5 (appendix p 33). APOA: apolipoprotein A. APOB: apolipoprotein B. BMI: Body mass index. CRP: C-reactive protein. FEV1: Forced expiratory volume during one second. FVC: Forced vital capacity. HbA1c: Haemoglobin A1c (glycated haemoglobin). HDL: high density lipoprotein. LDL: low density lipoprotein. Lp(A): lipoprotein A. WC: waist circumference. WHR: waist-hip ratio. WMH: white matter hyperintensity.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

Sorted by citations

See all 317

Metadata

Authors
Lumsden, A. L., Mulugeta, A., Zhou, A., & Hyppönen, E.
Affiliations
University of South Australia (AU)
Corresponding author
Hyppönen, Elina
Venue
eBioMedicine
Publisher
Elsevier BV
Published
2020-09
Volume
59
Pages
102954
ISSN
2352-3964 (ISSN-L)
OpenAlex
W3069395596
Cited by
317
References
31
Citations by year
2026: 54 · 2025: 72 · 2024: 82 · 2023: 59 · 2022: 33 · 2021: 17
FWCI
3.88
Type
journal article
Language
en
Open access
Locations
  • EBioMedicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • UniSA Research Outputs Repository (University of South Australia) (submittedVersion, other-oa)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • UK Biobank (GNT1123603)
  • National Health and Medical Research Council (GNT1157281)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
apolipoprotein E, APOE genotype, APOE ε4, APOE ε2, Alzheimer's disease, hypercholesterolemia, ischemic heart disease, phenome-wide association study, disease risk, obesity, type 2 diabetes, peripheral vascular disease, thromboembolism, arterial aneurysm, peptic ulcer, hallux valgus, cardiovascular disease, genetic risk factors
MeSH terms
Adult, Aged, Alleles, Apolipoproteins E, Female, Genotype, United Kingdom, Humans, Male, Middle Aged, Phenotype, Population Surveillance, Registries, Risk Factors, Case-Control Studies, Biological Specimen Banks, Risk Assessment, Genetic Predisposition to Disease, Genetic Association Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review